MedWatch

A part of Watch Media

Boehringer Ingelheim inks third collab in four years with Danish biotech company

Another deal has fallen into place between Boehringer Ingelheim and the Danish biotech and contract research firm Gubra. The parties have entered into lucrative deals in the past, but will not disclose the financial terms underlying the new agreement.

Photo: Gubra / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Danish biotech and contract research firm Gubra has signed a new agreement with German pharmaceutical giant Boehringer Ingelheim on the development of peptide compounds for treating obesity, according to a joint press announcement from the companies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

  1. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  2. FDA approves new sensor for insulin pens
  3. Full house for Ambu – all products live up to new EU requirements
  4. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  5. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  6. New majority owner makes several board appointments at hearing firm
  7. FDA awards Pfizer's RSV vaccine candidate priority review status
  8. More countries back EU Commission investigation into potential Oticon sale
  9. Nobel Prize winner: "Good research is driven by curiosity"
  10. Forward Pharma's last hope in protracted Biogen battle extinguished
  11. FDA ruling to trigger royalty payments for Novo Nordisk
  12. Federal court throws out cancer cases against GSK, Sanofi and Pfizer
  13. Coloplast deputy chair spends USD 7m on shares in firm
  14. USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug
  15. Biogen and Sage complete FDA rolling submission of depression drug

See all

Job

See all jobs

See all jobs